单株抗体疗法市场－全球产业规模、份额、趋势、机会及预测（按产品类型、应用、生产来源、最终用户、地区和竞争格局划分，2021-2031年）

全球单株抗体治疗市场预计将从 2025 年的 2,472.1 亿美元成长到 2031 年的 4,256.7 亿美元，复合年增长率为 9.48%。

これらの治疗薬は、标的细胞を攻撃する免疫システムの机能を回復・强化・模仿する代替抗体として机能するよう、実験室で设计された分子で构成されています。この市场成长は主に、がんや自体免疫疾患を含む慢性疾患の発生率上昇により、标的を绞った医疗介入への强いニーズが生じていること、および高齢化が进む世界人口が老龄化に伴う疾患の効果的な管理を特定の生物学的治疗を通じて求めていることが主な要因です。

然而，市场面临与研发和生产相关的高成本等重大障碍，这可能限制患者的广泛用药，并加重医疗预算负担。严格的监管标准进一步加剧了这些财务挑战，延长了核准流程。为了凸显产业为克服这些挑战所做的持续努力，抗体协会报告称，美国食品药物管理局(FDA) 在 2024 年核准了15 种治疗性抗体分子，这表明业界正持续努力应对监管方面的复杂问题，并将新的治疗方法带给患者。

市场驱动因素

全球单株抗体疗法市场的主要驱动力是个人化医疗和标靶治疗的日益普及，而这又源自于对疾病发病机制更深入的临床理解。医疗服务提供者越来越重视生物製药製剂，领先的查核点抑制剂的成功，尤其是在肿瘤学和免疫学领域，便是最好的证明。默克在2024年2月发布的报告也印证了对高活性重磅药物的依赖，该报告预测，Keytruda的全球年销售额将在2023年增长19%，达到250亿美元。

同时，旨在加速新一代抗体偶联物（ADC）研发的策略性授权协议和合作正在重塑竞争格局。大型製药公司正积极寻求收购，以避免漫长的药物研发阶段并确保宝贵的在研产品线。例如，辉瑞公司于2023年12月宣布，已完成对SeeGen的收购，企业价值约430亿美元，使其肿瘤领域的资源翻了一番。这股势头在隔年得以延续。艾伯维公司在2024年2月的新闻稿中宣布，已完成对Immunogen的收购，总对价约101亿美元，凸显了对拓展ADC能力的重视。

市场挑战

全球单株抗体疗法市场的成长受到研发和生产这些复杂生物药物所需巨额资本成本的显着限制。与化学合成的小分子药物不同，单株抗体依赖使用活细胞的复杂生产工艺，需要严格的环境控制、昂贵的纯化系统和严苛的品质保证。这种复杂性需要大量的资本投入，从而设置了很高的准入门槛，阻碍了小型生物技术公司的参与，并导致市场力量集中，最终限制了能够降低价格的竞争多样性。

高昂的营运成本导致最终治疗产品价格居高不下，严重阻碍了市场渗透，限制了病患的用药机会。医疗系统和私人支付者通常会设定严格的报销标准以控製成本，导致许多合格的患者无法获得所需的治疗。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，欧洲以研发为基础的製药业预计将在研发方面投入550亿欧元，凸显了创新所需的巨额资金。这些财务压力迫使製造商维持高价以收回投资，直接阻碍了对成本敏感的市场的产品普及率和销售量成长。

市场趋势

将人工智能融入抗体工程和药物发现领域，正从根本上改变着药物研发模式，它能够从头设计出具有超越传统筛检技术的优化特性的生物製药。製药公司正积极利用生成式人工智慧模型来预测蛋白质结构和结合亲和性，进而缩短研发週期，并提高复杂多特异性抗体的成功率。这一趋势在对Xaira Therapeutics等人工智慧原生生物技术公司的大规模投资中可见一斑。根据Fierce Biotech 2024年4月的一篇报导报道，该公司已筹集超过10亿美元资金，并开始建立一个整合的、人工智慧驱动的药物研发平台。

同时，市场正策略性地向神经退化性疾病领域扩张，挑战免疫学和肿瘤学领域的传统主导地位。近期，阿兹海默症疾病修正治疗的核准，证明了单克隆抗体在清除β-淀粉样斑块和延缓认知衰退方面的疗效，标志着该领域的一次决定性转变。这种潜力已开始在营收数据中显现。百健公司在2024年10月公布的数据显示，其Rekembi第三季全球市场销售额达到约6,700万美元，显示患者对此创新神经系统疗法的接受度高，且相关基础设施已相当完善。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球单株抗体治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（裸抗体、融合蛋白、抗体片段、偶联物、多特异性抗体）
  • 用途别（がん、自体免疫疾患、感染疾病、その他）
  • 依生产来源（人类来源、人源化、嵌合体、其他）
  • エンドユーザー别（病院、専门医疗センター、研究机関）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美单株抗体治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲单株抗体治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区单株抗体疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲单株抗体治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲单株抗体治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球单株抗体疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi SA
• AstraZeneca inc.
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Monoclonal Antibody Therapeutics Market is projected to expand from USD 247.21 Billion in 2025 to USD 425.67 Billion by 2031, reflecting a compound annual growth rate of 9.48%. These therapeutics consist of molecules engineered in laboratories to function as substitute antibodies that can restore, enhance, or mimic the immune system's ability to attack target cells. This market growth is principally driven by the rising incidence of chronic diseases, including cancer and autoimmune disorders, which create a strong need for targeted medical interventions, alongside a growing global geriatric population that demands effective management of age-related illnesses through specific biologic treatments.

However, the market encounters substantial obstacles related to the high costs inherent in development and manufacturing, which can restrict widespread patient access and impose strain on healthcare budgets. These financial hurdles are further complicated by stringent regulatory standards that extend the duration of the approval process. Highlighting the industry's continued dedication to overcoming these challenges, The Antibody Society reported that the US FDA approved 15 therapeutic antibody-based molecules in 2024, signaling sustained efforts to navigate regulatory complexities and bring new treatments to patients.

Market Driver

A primary catalyst for the global monoclonal antibody therapeutics market is the rising adoption of personalized medicine and targeted therapies, driven by a deeper clinical understanding of disease pathology. Healthcare providers are increasingly prioritizing biologics that deliver precise mechanisms against specific antigens, particularly within the fields of oncology and immunology, as evidenced by the success of leading checkpoint inhibitors. This reliance on high-efficacy blockbusters to meet critical unmet needs is illustrated by Merck & Co.'s report in February 2024, which noted that worldwide sales of Keytruda rose by 19 percent to reach $25.0 billion for the full year 2023.

Concurrently, the competitive landscape is being reshaped by strategic licensing agreements and collaborations aimed at accelerating the development of next-generation antibody-drug conjugates (ADCs). Major pharmaceutical companies are actively pursuing acquisitions to bypass lengthy discovery phases and secure valuable pipeline assets, a trend exemplified by Pfizer Inc.'s announcement in December 2023 that it completed the acquisition of Seagen for an enterprise value of approximately $43 billion to double its oncology resources. This momentum continued into the following year, as noted in a February 2024 press release from AbbVie Inc., which confirmed the finalization of its acquisition of ImmunoGen for a total equity value of roughly $10.1 billion, underscoring the intense focus on expanding ADC capabilities.

Market Challenge

The growth of the Global Monoclonal Antibody Therapeutics Market is heavily constrained by the immense financial costs involved in developing and manufacturing these complex biologic drugs. In contrast to chemically synthesized small molecules, monoclonal antibodies depend on intricate production methods using living cells, requiring strict environmental controls, costly purification systems, and rigorous quality assurance. This complexity necessitates significant capital expenditure, establishing high entry barriers that deter smaller biotechnology firms and consolidate market power, effectively limiting the competitive diversity required to foster price reductions.

These steep operational costs result in high prices for final therapeutic products, which severely limits market penetration and restricts patient access. Healthcare systems and private payers frequently impose stringent reimbursement criteria to control expenses, leaving many eligible patients without necessary treatments. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe in 2024, highlighting the substantial capital required for innovation; such financial pressure compels manufacturers to sustain high prices to recover investments, which directly impedes adoption rates and volume growth in cost-sensitive markets.

Market Trends

The integration of artificial intelligence into antibody engineering and discovery is fundamentally transforming the development model by allowing for the de novo design of biologics with optimized traits, surpassing traditional screening techniques. Pharmaceutical entities are increasingly utilizing generative AI models to forecast protein structures and binding affinities, thereby shortening development timelines and enhancing success rates for complex multispecific antibodies. This trend is highlighted by significant investment in AI-native biotech firms, such as Xaira Therapeutics, which, according to a Fierce Biotech article from April 2024, launched with over $1 billion in committed capital to establish an integrated AI-driven drug development platform.

In parallel, the market is undergoing a strategic expansion into neurodegenerative disorders, challenging the historical dominance of immunology and oncology indications. Recent regulatory approvals for disease-modifying Alzheimer's therapies have validated the effectiveness of monoclonal antibodies in removing amyloid-beta plaques and slowing cognitive decline, creating a pivotal shift in the sector. This potential is beginning to reflect in revenue data, as Biogen Inc. reported in October 2024 that global in-market sales of Leqembi reached approximately $67 million for the third quarter, indicating strong patient uptake and infrastructure readiness for these innovative neurologic treatments.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A
• AstraZeneca inc.
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc.

Report Scope

In this report, the Global Monoclonal Antibody Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibody Therapeutics Market, By Product Type

• Naked
• Fusion Protein
• Antibody Fragment
• Conjugate
• Multi-specific

Monoclonal Antibody Therapeutics Market, By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

Monoclonal Antibody Therapeutics Market, By Production Source

• Human
• Humanized
• Chimeric
• Others

Monoclonal Antibody Therapeutics Market, By End User

• Hospital
• Specialty Centers
• Research Institutes

Monoclonal Antibody Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibody Therapeutics Market.

Available Customizations:

Global Monoclonal Antibody Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibody Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-specific)
  • 5.2.2. By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Others)
  • 5.2.3. By Production Source (Human, Humanized, Chimeric, Others)
  • 5.2.4. By End User (Hospital, Specialty Centers, Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Monoclonal Antibody Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Production Source
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Production Source
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Production Source
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Monoclonal Antibody Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Production Source
      • 6.3.3.2.4. By End User

7. Europe Monoclonal Antibody Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Production Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Production Source
      • 7.3.1.2.4. By End User
  • 7.3.2. France Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Production Source
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Production Source
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Production Source
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Monoclonal Antibody Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Production Source
      • 7.3.5.2.4. By End User

8. Asia Pacific Monoclonal Antibody Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Production Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Production Source
      • 8.3.1.2.4. By End User
  • 8.3.2. India Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Production Source
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Production Source
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Production Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Monoclonal Antibody Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Production Source
      • 8.3.5.2.4. By End User

9. Middle East & Africa Monoclonal Antibody Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Production Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Production Source
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Production Source
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Monoclonal Antibody Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Production Source
      • 9.3.3.2.4. By End User

10. South America Monoclonal Antibody Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Production Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Production Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Production Source
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Monoclonal Antibody Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Production Source
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Monoclonal Antibody Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co. Inc.
• 15.4. Pfizer Inc.
• 15.5. Eli Lilly and Co.
• 15.6. Sanofi S.A
• 15.7. AstraZeneca inc.
• 15.8. Bayer AG
• 15.9. Regeneron Pharmaceuticals Inc.
• 15.10. GSK Plc.

16. Strategic Recommendations

17. About Us & Disclaimer